Novel AAV capsids for intravitreal gene therapy of photoreceptor disorders

Gene therapy using recombinant adeno‐associated virus (rAAV) vectors to treat blinding retinal dystrophies has become clinical reality. Therapeutically impactful targeting of photoreceptors still relies on subretinal vector delivery, which detaches the retina and harbours substantial risks of collat...

Descripción completa

Detalles Bibliográficos
Autores principales: Pavlou, Marina, Schön, Christian, Occelli, Laurence M, Rossi, Axel, Meumann, Nadja, Boyd, Ryan F, Bartoe, Joshua T, Siedlecki, Jakob, Gerhardt, Maximilian J, Babutzka, Sabrina, Bogedein, Jacqueline, Wagner, Johanna E, Priglinger, Siegfried G, Biel, Martin, Petersen‐Jones, Simon M, Büning, Hildegard, Michalakis, Stylianos
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8033523/
https://www.ncbi.nlm.nih.gov/pubmed/33616280
http://dx.doi.org/10.15252/emmm.202013392

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8033523/
https://www.ncbi.nlm.nih.gov/pubmed/33616280
http://dx.doi.org/10.15252/emmm.202013392

Ejemplares similares